Table 2.
Estimated changes in targeted therapies utilisation following changes in reimbursement policies using segmented regression models
| Intercept | Baseline trend | Effects of intervention (1) erlotinib covered by NHI (third-line) (200 706) | Effects of intervention (2) gefitinib became second-line treatment (200 711) | Effects of intervention (3) erlotinib became second-line treatment (200 806) | Effects of intervention (4) gefitinib became first-line treatment (201 106) | |||||||||
| Level change | Trend change | Relative change (3 months later) |
Level change | Trend change | Relative change (3 months later) |
Level change | Trend change | Relative change (3 months later) |
Level change | Trend change | Relative change (3 months later) |
|||
| Prescribing rate of targeted therapies | 0.0342 | 0.0041 (0.0021 to 0.0060) |
NS | NS | NS | NS | 0.0121 (0.0027 to 0.0215) |
15.58% | NS | −0.0140 (−0.0226 to −0.0054) |
−10.98% | 0.0264 (0.0037 to 0.0491) |
NS | 6.31% |
| Prescribing rate of gefitinib | 0.0263 | 0.0042 (0.0017 to 0.0067) |
NS | −0.0146 (−0.0268 to –0.0024) |
−20.69% | NS | 0.0210 (0.0048 to 0.0372) |
54.32% | NS | −0.0112 (−0.0211 to –0.0013) |
−13.27% | 0.0215 (0.0026 to 0.0404) |
0.0072 (0.0032 to 0.0113) |
21.76% |
| Prescribing rate of erlotinib | 0.0099 | 0.0127 (0.0059 to 0.0195) |
NA | NA | NA | NS | −0.0100 (−0.0173 to –0.0026) |
−26.79% | 0.0228 (0.0060 to 0.0396) |
NS | 22.62% | NS | −0.0076 (−0.0105 to –0.0048) |
−10.30% |
| Market share by cost for targeted therapies | 0.0446 | 0.0068 (0.0045 to 0.0091) |
NS | NS | 0 | NS | NS | 0 | NS | −0.0062 (−0.0095 to –0.0028) |
−4.33% | NS | NS | 0 |
| Market share by cost for gefitinib | 0.1030 | 0.0043 (0.0014 to 0.0072) |
NS | −0.0064 (−0.0106 to –0.0023) |
−6.59% | NS | NS | 0 | NS | NS | 0 | NS | 0.0095 (0.0052 to 0.0137) |
16.63% |
| Market share by cost for erlotinib | 0.0194 | 0.0202 (0.0113 to 0.0291) |
NA | NA | NA | NS | −0.0183 (−0.0278 to –0.0088) |
−30.33% | 0.0302 (0.0077 to 0.0527) |
NS | 21.66% | NS | −0.0074 (−0.0108 to –0.0040) |
−9.30% |
Relative changes = (actual value − predicted value) in outcomes 3 months following the interventions/predicted value in outcomes 3 months following the interventions
NA, not available; NHI, National Health Insurance; NS, not significant.